Literature DB >> 7753696

Effect of blood pressure cuffs on neonatal circulation: their potential application to newborns with persistent pulmonary hypertension.

J Rhodes1, J T Wung, F Z Bierman.   

Abstract

The contribution of vasoactive pharmacologic agents to the care of the infant with primary pulmonary hypertension of the newborn (PPHN) is hampered by their limited ability to act selectively on different vascular beds. In contrast, blood pressure (BP) cuffs decrease flow and increase resistance only in the extremities around which they are applied. They therefore offer a means of increasing systemic vascular resistance without affecting pulmonary vascular resistance, a hemodynamic effect that may be particularly desirable among PPHN patients receiving vasodilators. We studied the effect of BP cuffs on the circulation of nine healthy neonates and three infants with severe PPHN. Among the healthy neonates, inflation of the cuffs to 20 mmHg had no discernible hemodynamic effect. Inflation to systolic pressures, however, caused the left ventricular preejection period to increase from 36 +/- 9 ms to 45 +/- 10 ms, the end-diastolic dimension to increase from 1.80 +/- 0.16 cm to 1.92 +/- 0.16 cm, and the cardiac output to fall to 87 +/- 12% of baseline (all p < 0.05)--changes indicative of an increase in systemic vascular resistance. Application of BP cuffs to the patients with PPHN was associated with 10-25 mmHg increases in transcutaneous arterial oxygen tensions. Administration of tolazoline to these patients while the cuffs were inflated resulted in additional 10-20 mmHg increases and did not precipitate hypotension. These observations suggest that BP cuffs can play a useful role in the management of patients with PPHN.

Entities:  

Mesh:

Year:  1995        PMID: 7753696     DOI: 10.1007/BF02310329

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  14 in total

1.  Blood flow in the foot and calf of the newborn. A plethysmographic study.

Authors:  O CELANDER
Journal:  Acta Paediatr       Date:  1960-07       Impact factor: 2.299

2.  Application of the medical anti-shock trouser (MAST) increases cardiac output and tissue perfusion in simulated, mild hypovolaemia.

Authors:  D Mannering; E D Bennett; N Mehta; A L Davis
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

3.  The circulation of the fetus in utero. Methods for studying distribution of blood flow, cardiac output and organ blood flow.

Authors:  A M Rudolph; M A Heymann
Journal:  Circ Res       Date:  1967-08       Impact factor: 17.367

Review 4.  Persistent pulmonary hypertension of the newborn.

Authors:  L J Tiefenbrunn; T A Riemenschneider
Journal:  Am Heart J       Date:  1986-03       Impact factor: 4.749

Review 5.  Persistent pulmonary hypertension in the neonate: diagnosis and management.

Authors:  W W Fox; S Duara
Journal:  J Pediatr       Date:  1983-10       Impact factor: 4.406

6.  Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.

Authors:  D J Sahn; A DeMaria; J Kisslo; A Weyman
Journal:  Circulation       Date:  1978-12       Impact factor: 29.690

7.  Limb blood flow in the normal and sick newborn. A plethysmographic study.

Authors:  L Kidd; H Levison; P Gemmel; A Aharon; P R Swyer
Journal:  Am J Dis Child       Date:  1966-11

Review 8.  Persistent pulmonary hypertension in the neonate.

Authors:  E D Graves; C R Redmond; R M Arensman
Journal:  Chest       Date:  1988-03       Impact factor: 9.410

9.  Hemodynamic effects of Medical Anti-Shock Trousers (MAST garment).

Authors:  F A Gaffney; E R Thal; W F Taylor; B C Bastian; J A Weigelt; J M Atkins; C G Blomqvist
Journal:  J Trauma       Date:  1981-11

10.  The independent effects of hyperventilation, tolazoline, and dopamine on infants with persistent pulmonary hypertension.

Authors:  W H Drummond; G A Gregory; M A Heymann; R A Phibbs
Journal:  J Pediatr       Date:  1981-04       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.